Non-small cell lung cancer: An overview of current management

European Journal of Cancer Part A

Volumn 33, Issue SUPPL. 1, 1997, Pages

  Dancey, J ^a   Le Chevalier, T ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Non small cell lung cancer; Radiotherapy; Review

Indexed keywords

CISPLATIN;

CONFERENCE PAPER; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0030892404     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00325-5     Document Type: Conference Paper

References (88)

1. Boring CC, Squires TS, Tong TT, et al. Cancer Statistics. CA 1994, 44, 7-26.
2. Ginsberg, RJ, Kris MG, Armstrong JG. Non-small cell lung cancer. In Cancer Principles & Practice of Oncology, 4th Edn. VT DeVita Jr, S Hellman, SA Rosenberg eds. Philadelphia, J.B. Lippincott Company, 1994, 673.
3. Boffetta P, La Vecchia C, Levi F, Lucchini F. Mortality patterns and trends for lung cancer and other tobacco-related cancers in the Americas 1955-1989. Int J Epidemiol 1993, 22, 377-384.
4. Green MR. New directions for chemotherapy in non-small cell lung cancer. Chest 1993, 103, 370s-372s.
5. Bulzebruck H, Bopp R, Drings P, et al. New aspects in staging of lung cancer. Cancer 1992, 70, 1102-1110.
6. Mount CF. A new international staging system for lung cancer. Chest 1986, 89 (suppl), 225-233.
7. Naruke T, Goya T, Tsuchiya R, et al. Prognosis and survival in resected lung carcinoma based on the international staging system. J Thorac Cardiovasc Surg 1988, 96, 440-447.
8. Peterson GM. Epidemiology, screening and prevention of lung cancer. Curr Opin Oncol 1994, 6, 156-161.
9. Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed countries: indirect estimation from national vital statistics. Lancet 1992, 339, 1268-1278.
10. Tirmarche M, Raphalen A, Allin F, Chameaud J, Bredon P. Mortality of a cohort of French uranium miners exposed to relatively low radon concentrations. Br J Cancer 1993, 67, 1090-1097.
11. Ward E, Okur A, Ruder A, Fingerhut M, Steenland K. A mortality study of workers at seven beryllium processing plants. Am J Ind Med 1992, 22, 885-904.
12. Chen R, Wei L, Huang H. Mortality from lung cancer among copper miners. Br J Med 1993, 50, 505-509.
13. Moulin JJ, Wild P, Mantout B, Fournier-Betz M, Mur JM, Smagghe G. Mortality from lung cancer and cardiovascular diseases among stainless steel producing workers. Cancer Causes Control 1993, 4, 75-81.
14. Halpern MT, Gillespie BW, Warner KE. Patterns of absolute risk of lung cancer mortality in former smokers. J Natl Cancer Inst 1994, 85, 457-464.
15. Tweedie RL, Mengersen KL. Lung cancer and passive smoking: reconciling the biochemical and epidemiological approaches. Br J Cancer 1992, 66, 700-705.
16. Richardson GE, Johnson BE. The biology of lung cancer. Semin Oncol 1993, 20, 105-127.
17. Sundaresan V, Heppell-Parton A, Coleman N, et al. Somatic genetic changes in lung cancer and precancerous lesions. Ann Oncol 1995 (Suppl 1), 6, s27-s32.
18. Carbone DP, Minna JD. The molecular genetics of lung cancer. Science 1989, 246, 491-494.
19. Strauss GM, Kwiatkowoski DJ, Harpole DH, et al. Molecular and pathological markers in stage I non-small cell carcinoma of the lung. J Clin Oncol 1995, 3, 1265-1279.
20. Slebos RJC, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323, 561-565.
21. Mitsudomi T, Steinberg SM, Oie HK, et al. Ras gene mutations in non small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 1991, 51, 4999-5002.
22. Kenji S, Ishida T, Yokoyaina H, Inoue Y, Sugimachi K, Sasazuki T. Ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992, 52, 2903-2906.
23. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993, 8, 2407-2412.
24. McClaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 1992, 66, 735-738.
25. Quintan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992, 52, 4828-4831.
26. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 1993, 53, 1-4.
27. Chiba I, Takahashi T, Nau NW, et al. Mutations in p53 are frequent in primary, resected, non-small cell lung cancer. Lung Cancer Study Group. Oncogene 1990, 5, 1603-1610.
28. Mukhopadhyay T, Tainsky M, Cavender AC, et al. Specific inhibition of k-ras expression and tumorgenicity of lung cancer by antisense RNA. Cancer Res 1991, 51, 1744-1749.
29. Takahashi T, Carbone D, Takahashi T, et al. Wildtype but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 1992, 52, 2340-2343.
30. Fujiwara T, Cai DW, Georges RN, et al. Therapeutic effects of a retroviral wild type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994, 86, 1458-1462.
31. Clayman GI, EI-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995, 55, 1-6.
32. Carbone DP, Minna JD. In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst 1994, 86, 1437-1438.
33. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311, 899-909.
34. Shepherd F. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 1993, 55, 1585-1592.
35. Burkes RL, Ginsberg JF, Shepherd FA, et al. Induction chemotherapy with mitomycin, vindesine and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II trial. J Clin Oncol 1992, 10, 550-586.
36. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994, 330, 153-158.
37. Roth J, Fossella F, Komaki R, et al. A randomized trial comparing peroperative chemotherapy and surgery with surgery alone in resectable stage III non-small cell lung cancer. J Natl Cancer Inst 1994, 86, 673-680.
38. Pass H, Pogrebniak H Steinberg S, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 1992, 53, 992-998.
39. Cardiello C, Blanco Villaba J, Anac S, et al. Combined radiochemotherapy (RtCt) versus radiotherapy (Rt) in limited inoperable non-small cell carcinoma of the lung (NSCLC). Proc Am Soc Clin Oncol 1985, 4, C692 (Abstract).
40. Van Houtte P, Klastersky J, Renoud A, et al. Induction chemotherapy with cisplatin, etoposide and vindesine before radiation therapy for non-small cell lung cancer. Treatment modalities in lung cancer. Antibiot Chemother 1988, 41, 131-137.
41. Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988, 24, 477-482.
42. Alberti W, Niederle N, Budach V, Konietzko N, Sack H. Prospective randomised study comparing immediate radiotherapy (RT), chemo plus radiotherapy (CT + RT) or delayed radiotherapy in non-small cell lung cancer. J Cancer Res Clin Oncol I 1990, 16 (part 1), 503.
43. Brodin O, Nou E for the Swedish Multicentre Group for the Study of Squamous Cell Carcinoma of the Lung. Patients with nonresectable squamous cell carcinoma of the lung. A prospective randomized study. Lung Cancer 1991, 7, 165.
44. Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy in localized inoperable non small cell lung cancer: a randomized trial. J Natl Cancer Inst 1993, 85, 997-999.
45. Crino L, Latini P, Meacci M, et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small cell lung cancer. Ann Oncol 1993, 4, 847-851.
46. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990, 323, 940-945.
47. Dillman RO, Seagren SL, Herndon J, Green MR. Randomized trial of induction chemotherapy plus radiation therapy vs. RT alone in stage III non-small cell lung cancer (NSCLC): five year follow up of CALGB 84-33. Proc Am Soc Clin Oncol 1993, 12, abstract no 1092.
48. le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung carcinoma: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83, 417-423.
49. le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Natl Cancer Inst 1994, 86, 58.
50. Souse W, Scott C, Taylor S, et al. RTOG 8808 ECOG 4588, preliminary analysis of phase III trials in regionally advanced unresectable non-small cell lung cancer. Lung Cancer 11 (Suppl 1), 179 (Abstract).
51. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992, 326, 524-530.
52. Blanke C, Ansar R, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995, 13, 1609-1614.
53. Einhorn LH, Loehrer PJ, Williams SD, et al. Random prospective study of vindesine versus vindesine plus high dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non small cell lung cancer. J Clin Oncol 1986, 4, 1037-1043.
54. Luedke DW, Einhorn L, Omura GA, et al. Randomized comparison of two combination regimens versus minimal chemotherapy in non small cell lung cancer: a Southeastern Cancer Study Group Trial. J Clin Oncol 1990, 8, 886-891.
55. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced nonsmall-cell lung cancer report of a Canadian multicenter randomized trial. J Clin Oncol 1988, 6, 633-641.
56. Kris MG, Gralla RJ, Kalman LA, et al. Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 1985, 69, 387-395.
57. Dhingra HM, Valdivieso M, Carr DT, et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985, 3, 1761-1783.
58. Hainsworth JD, Johnson DH, Hande KR, et al. Chemotherapy of advanced non-small cell lung cancer: a randomized trial of three cisplatin-based chemotherapy regimens. Am J Clin Oncol 1989, 12, 345-349.
59. Ruckdeschel JC, Finkelstein DM, Ettinger DS, et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 1986, 4, 14-22.
60. Paccagnella A, Brandes A, Pappagallo GL, et al. Cisplatin plus vindesine versus cisplatin plus VP-16 versus doxorubicin plus cytoxan in non-small cell carcinoma of the lung. A randomized study. Tumori 1986, 72, 417-425.
61. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12, 360-367.
62. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT II, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992, 10, 16-20.
63. Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994, 12, 347-352.
64. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12, 1535-1540.
65. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12, 1821-1826.
66. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 1995, 13, 645-651.
67. Fossella FV, Lee JS, Murphy WX, et al. Phase II study of docetaxel in patients with stage IIIB and IV non-small cell lung cancer. J Clin Oncol 1994, 12, 1232-1237.
68. Murphy WK, Fossella FV, Winn RJ, et al. Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993, 85, 384-388.
69. Hainsworth JD, Thompson DS, Greco RA. Paclitaxel by 1 hour infusion: an active drug in metastatic nonsmall cell lung cancer. J Clin Oncol 1995, 13, 1609-1614.
70. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol Cancer Clin Trials, 1991, 14, 115-119.
71. Depierre A, Chastang C, Quiox E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non small cell lung cancer: a randomized trial. Ann Oncol 1994, 5, 37-42.
72. Osoba D. Measuring the effect of cancer on quality of life. In Osoba D, ed. Effect of Cancer on Quality of Life. Boca Raton, CRC Press, 1991, 26-40.
73. Levine MN. Incorporation of quality of life assessment into clinical trials. In Osoba D, ed. Effect of Cancer on Quality of Life. Boca Raton, CRC Press, 1991, 106-111.
74. Bergman B, Aaronson NK. Quality of life and cost effectiveness assessment in lung cancer. Curr Opin Oncol 1995, 7, 138-143.
75. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small cell lung carcinoma: univariate and multivariate analyses including recursive and amalgamation algorithms in 1052 patients. J Clin Oncol 1995, 13, 1221-1230.
76. Fernandez C, Rosell R, Abad-Esteve A, et al. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989, 28, 29-33.
77. Osoba D, Rusthoven JJ, Tumbull KA, et al. Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 1985, 3, 1478-1468.
78. Aaronson NK, Ahmedzai S, Bergman B, et al. for the The European Organization for Research and Treatment of Cancer Study Group on Quality of Life QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85, 365-375.
79. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. EORTC QLQ LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994, 30A, 635-642.
80. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. A concise QL-Index for use by physicians. J Chronic Disease 1989, 34, 585.
81. Wood-Dauphinee W, Williams JI. The Spitzer quality of life index: its performance as a measure. In Osoba D, ed. The Effect of Cancer on Quality of Life. Boca Raton, CRC Press, 1991, 169-184.
82. Moinpour CM. Measuring quality of life: an emerging science. Sem Oncol 1994, 21 (Suppl.) 48-63.
83. Brundage M, Davidson J. What survival advantage justifies combined chemotherapy and radiation therapy for locally advanced non-small cell lung cancer? Proc Am Soc Clin Oncol 1995, 14, 325 (Abstract 1728).
84. Jaakimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial. J. Clin Oncol 1988, 6, 633-641.
85. Smith TJ, Hillner BE, Neighbors DM, et al. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small cell lung cancer. J Clin Oncol 1995, 13, 2166-2173.
86. Gulati SC, Bitran JD. Cost effectiveness analysis: sleeping with an enemy or a friend? J Clin Oncol 1995, 13, 2152-2154.
87. Smith TJ, Hillner BE, Desch CE. Efficacy and cost-effectiveness in oncology: rational allocation of cancer care resources. J Natl Cancer Inst 1993, 85, 1460-1474.
88. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines using clinical and economic evaluation. Can Med Assoc J 1992, 146, 77-84.